• By ICR Secretariat
• Posted Monday, June 26, 2023

FDA delays decision on GSK bone cancer drug acquired in $2B buyout

https://www.biopharmadive.com/news/gsk-fda-delay-decision-momelotinib-myelofibrosis/653212/

• The Food and Drug Administration has delayed an approval decision for an experimental drug GSK is developing for a type of bone marrow cancer, so it can review new data submitted by the pharmaceutical company.